BELLE-3: A phase III study of buparlisib plus fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment

被引：24

作者：

Di Leo, A.

Lee, K. Seok

Ciruelos, E.

Lonning, P.

Janni, W.

O'Regan, R.

Reynier, M-A Mouret

Kalev, D.

Egle, D.

Csoszi, T.

Bordonaro, R.

Decker, T.

Tjan-Heijnen, V. C.

Blau, S.

Schirone, A.

Weber, D.

El-Hashimy, M.

Dharan, B.

Sellami, D.

Bachelot, T.

机构：

[1] Osped Misericordia Dolce, Prato, Italy

[2] Natl Canc Ctr, Gyeonggi, South Korea

[3] Hosp Univ 12 Octubre, Madrid, Spain

[4] Haukeland Hosp, Bergen, Norway

[5] Univ Ulm Klinikum, Ulm, Germany

[6] Univ Wisconsin, Madison, WI 53706 USA

[7] Ctr Jean Perrin, Clermont Ferrand, France

[8] Med Univ Varna, Varna, Bulgaria

[9] Univ Frauenklin Innsbruck, Innsbruck, Austria

[10] JNSZ Megyei Hetenyi Geza Korhaz, Rendelointezet, Szolnok, Hungary

[11] ARNAS Garibaldi, Catania, Italy

[12] Onkonet Onkol Ravensburg, Ravensburg, Germany

[13] Maastricht Univ, Med Ctr, Maastricht, Netherlands

[14] LLC, Rainier Hematol Oncol Northwest Med Specialities, Tacoma, WA USA

[15] Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy

[16] Novartis Pharma AG, Basel, Switzerland

[17] Novartis Pharmaceut, E Hanover, NJ USA

[18] Ctr Leon Berard, Lyon, France

来源：

CANCER RESEARCH | 2017年 / 77卷

关键词：

Breast cancer; PI3K inhibitor; Fulvestrant; Buparlisib;

D O I：

10.1158/1538-7445.SABCS16-S4-07

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

S4-07

引用

页数：2